Certara, Inc. (CERT)

Over the past six months, Certara, Inc.'s stock has decreased by approximately 19.54%. More recently, in the last month, the stock saw a fall of about 27.86%. The company reported its Q3 2025 earnings on November 6, 2025, posting $0.14 EPS, beating analysts' consensus estimates of $0.11, and updated its full-year 2025 financial guidance. Analysts currently have a "Moderate Buy" consensus rating for Certara, with an average price target of $13.82. Insider selling has outweighed buying in the past three months, with insiders selling $559,366.00 in company stock.

Demand for Certara's products and services is closely tied to research and development (R&D) expenditures by biopharmaceutical companies, academic institutions, and government bodies. The company's revenue can be negatively impacted by any economic, competitive, regulatory, or other market factors that decrease customer R&D spending. Growing adoption of biosimulation solutions is expected to accelerate revenue and earnings growth. Certara's Q2 2025 earnings call highlighted strong software and services demand, particularly in QSP services and Simcyp software.

Certara, Inc. is a global leader in model-informed drug development, operating within the Technology Services sector. The company provides proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Certara's integrated platform is utilized by over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 to 70 countries. Major products and services include biosimulation software such as Simcyp, Phoenix PK/PD, D360, and Certara IQ. They also offer regulatory science and market access software like GlobalSubmit eCTD and Pinnacle 21, along with technology-enabled services including mechanistic biosimulation, drug development strategy, and regulatory operations.

Certara, Inc. has a comprehensive global presence, with its solutions used by customers in over 70 countries. The company has operations and dedicated teams across North America, Europe, and Asia-Pacific. Its corporate headquarters are located in Radnor, Pennsylvania, United States. Other office locations include the U.S., Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom.

Certara has received global workplace excellence awards, including Fortune's Best Workplaces in BioPharma™ 2023 and being certified as a Great Place to Work® for 2023-2024. In October 2025, Certara launched Certara IQ, an AI-powered Quantitative Systems Pharmacology (QSP) platform. The company's Simcyp PBPK platform also received European Medicines Agency (EMA) qualification.

Certara, Inc. has a significant institutional ownership, with 73.96% of the stock held by institutions. Major institutional owners include Wasatch Advisors Inc., BlackRock, Inc., The Vanguard Group, Inc., Dimensional Fund Advisors LP, ArrowMark Colorado Holdings LLC, Deerfield Management Company, L.p. (series C), iShares Core S&P Small-Cap ETF, and Teacher Retirement System Of Texas. The largest individual/VC shareholder is Arsenal Capital Investment VI LP, owning 22.82% of the company's shares.